CYP Inhibition/Induction Evaluation Services
CYP Inhibition Assay Services for Veterinary Drug Development
Assess the drug-drug interaction (DDI) risk of your veterinary candidates with comprehensive cytochrome P450 (CYP) inhibition assays. Our standardized in vitro protocols evaluate direct, time-dependent, and metabolism-dependent inhibition across major CYP enzymes, delivering the IC50 data you need to predict clearance and refine combination therapy strategies.
Why CYP Inhibition Matters
Cytochrome P450 enzymes are central to the metabolism of most drugs, including veterinary pharmaceuticals. When a new chemical entity inhibits one or more of these enzymes, it can alter the clearance of co-administered drugs, leading to unexpected exposure, toxicity, or loss of efficacy. For veterinary drug developers designing combination therapies, understanding this interaction potential early is critical to de-risking the development pathway.
In vitro CYP inhibition assays are widely used to study potential drug-drug and drug-botanical interactions. By measuring the decrease in metabolite formation in the presence of a test compound compared to a vehicle control, an IC50 value can be calculated. This value serves as a key parameter for predicting whether a candidate is likely to cause clinically relevant interactions in the target species.
Our CYP inhibition assay services provide the data you need to make informed decisions about candidate selection, combination therapy design, and the need for follow-up in vivo studies.
Reversible Inhibition Screening
Evaluate the direct, reversible inhibition potential of your compound against major CYP enzymes using established probe substrates.
- IC50 determination for major CYP isoforms
- Fluorescent or LC-MS/MS readouts
- Recombinant human CYP enzymes or human liver microsomes
Time-Dependent Inhibition (TDI)
Identify mechanism-based inhibitors that require metabolic activation to exert their effect, a critical distinction for predicting clinical DDI risk.
- Pre-incubation with NADPH to assess metabolism-dependent inhibition
- Shift in IC50 between pre-incubated and non-pre-incubated conditions
- Distinguishes reversible from irreversible inhibition
High-Throughput Cocktail Assays
Screen multiple CYP isoforms simultaneously using a cocktail of probe substrates, increasing throughput while conserving compound.
- Simultaneous assessment of multiple CYP enzymes
- Reduced compound consumption
- Streamlined LC-MS/MS analysis
Assay Formats and Readouts
We offer flexibility in assay format to match your stage of development and compound properties. Our standardized protocols are designed to generate high-quality, reproducible data that can be compared across projects and integrated into regulatory submissions.
The choice of format depends on factors such as compound solubility, autofluorescence, and the specific CYP isoforms of interest. Our scientific team can help you select the most appropriate approach for your candidate.
| Format | Enzyme Source | Readout | Best For |
|---|---|---|---|
| Fluorescent | Recombinant human CYP enzymes | Fluorescent metabolite formation | Early screening; high-throughput |
| LC-MS/MS | Human liver microsomes or recombinant enzymes | Quantitative metabolite formation | Definitive IC50; regulatory-grade data |
| Cocktail | Human liver microsomes | LC-MS/MS multiplexed analysis | Efficiency; multiple CYP isoforms at once |
| Time-Dependent | Human liver microsomes | IC50 shift with pre-incubation | Mechanism-based inhibition assessment |
How It Works
Our CYP inhibition assay service follows a structured workflow designed to deliver reliable, interpretable data. From study design to final report, each step is documented to support your regulatory submissions.
Study Design Consultation
We work with you to define the scope of the study, including the CYP isoforms to be evaluated, the assay format (fluorescent, LC-MS/MS, or cocktail), and the concentration range for your test compound. We also confirm the appropriate positive and negative controls for each enzyme.
Compound Preparation and Solubility Assessment
Your test compound is prepared in an appropriate solvent system. We assess solubility under assay conditions to ensure that the concentrations tested are meaningful and that precipitation does not confound the results.
Assay Execution
The inhibition assay is performed using validated protocols. For time-dependent inhibition studies, parallel incubations with and without NADPH pre-incubation are conducted. Metabolite formation is quantified using the chosen readout method.
Data Analysis and IC50 Calculation
The decrease in metabolite formation relative to vehicle control is used to calculate IC50 values. For time-dependent inhibition, the shift in IC50 between pre-incubated and non-pre-incubated conditions is reported.
Report and Interpretation
You receive a comprehensive report including raw data, calculated IC50 values, and an interpretation of the DDI risk. Our scientists are available to discuss the results and their implications for your development program.
Customization Options
Every development program has unique requirements. We offer a range of customization options to ensure that the data you receive is directly relevant to your questions and regulatory needs.
Whether you need to evaluate a specific CYP isoform, test a panel of compounds, or integrate data across multiple assays, our team can design a study that fits your objectives.
Custom CYP Panel
Select the specific CYP isoforms most relevant to your drug target and species. We can evaluate a single enzyme or a comprehensive panel.
- CYP1A2, 2C9, 2C19, 2D6, 3A4 and more
- Species-specific considerations for veterinary drugs
- Prioritization based on metabolic pathway data
Flexible Study Parameters
Adjust compound concentration ranges, incubation times, and protein concentrations to match your compound's properties and the stage of development.
- Multiple concentration points for robust IC50 curves
- Optional pre-incubation for TDI assessment
- Compatibility with cassette analysis for efficiency
Contextualized Reporting
Combine CYP inhibition data with other ADME endpoints to build a complete picture of your compound's interaction potential.
- Integration with metabolic stability and metabolite identification data
- Clear flagging of DDI risk levels
- Support for regulatory submissions
Regulatory Alignment
Our CYP inhibition assay protocols are designed to align with regulatory guidance for in vitro drug interaction studies. This alignment helps ensure that the data you generate is suitable for inclusion in regulatory submissions.
We follow standardized protocols for assessing direct, indirect, and time-dependent CYP inhibition, ensuring high-quality data that supports your development decisions.
| Guidance Element | Our Approach | Deliverable | Benefit |
|---|---|---|---|
| Probe Substrates | FDA-recommended probe substrates for major CYP isoforms | Validated assay conditions | Data comparability across studies |
| Positive Controls | Known inhibitors included in each assay run | Assay performance verification | Confidence in data quality |
| IC50 Calculation | Nonlinear regression analysis of inhibition curves | IC50 values with confidence intervals | Quantitative DDI risk assessment |
| TDI Assessment | Parallel incubations with and without NADPH pre-incubation | IC50 shift determination | Identification of mechanism-based inhibitors |
Applications Across Development
CYP inhibition data is valuable at multiple stages of veterinary drug development. From early screening to regulatory submission, our services provide the information you need to make confident decisions.
The versatility of our assay platform means we can support a wide range of project types, from single-compound evaluations to complex combination therapy assessments.
Early Candidate Screening
Identify CYP inhibition liabilities early in the discovery phase to guide structural modifications and select candidates with favorable DDI profiles.
- Rapid fluorescent-based screening
- Rank-ordering of analogs
- Early de-risking of combination therapies
DDI Risk Assessment for Combinations
Evaluate the interaction potential between components of a combination therapy to ensure safe and effective co-administration.
- Assessment of each component as both victim and perpetrator
- Identification of potential dose adjustments
- Support for rational combination design
Submission-Ready Data
Generate high-quality CYP inhibition data suitable for inclusion in regulatory dossiers, following established guidance and best practices.
- Documented protocols and raw data
- Clear interpretation of DDI risk
- Support for product labeling decisions
Comparison of Assay Approaches
Different assay formats offer distinct advantages depending on your stage of development and data requirements. The table below summarizes the key characteristics of each approach to help you select the right option.
Our scientific team can provide additional guidance on selecting the most appropriate format for your specific compound and development stage.
| Approach | Throughput | Data Quality | Recommended Use |
|---|---|---|---|
| Fluorescent Assay | High | Semi-quantitative | Early screening; rank-ordering |
| LC-MS/MS Assay | Medium | Quantitative, definitive | Regulatory-grade IC50 determination |
| Cocktail Assay | High | Quantitative | Efficient multi-isoform assessment |
| Time-Dependent Assay | Medium | Quantitative | Mechanism-based inhibition evaluation |
Quality and Reproducibility
Reliable CYP inhibition data depends on rigorous assay design and execution. Our protocols incorporate multiple quality control measures to ensure that the data you receive is accurate and reproducible.
Each assay run includes positive and negative controls to verify assay performance. We also assess compound solubility and stability under assay conditions to ensure that the results are not confounded by technical artifacts.
Our commitment to quality means you can trust the data to support your critical development decisions.
Data Interpretation Support
Interpreting CYP inhibition data requires an understanding of the assay limitations and the context of your specific development program. Our scientists provide clear, actionable interpretation of your results.
We help you understand what the IC50 values mean for your compound's DDI risk, how to compare results across different CYP isoforms, and what follow-up studies may be warranted.
FAQ
What is the difference between direct and time-dependent CYP inhibition?
Direct (reversible) inhibition occurs when a compound binds to the enzyme and reduces its activity without forming a covalent bond. Time-dependent inhibition (TDI) often involves metabolism of the inhibitor to a reactive intermediate that irreversibly inactivates the enzyme. TDI is assessed by comparing IC50 values with and without NADPH pre-incubation; a significant shift indicates mechanism-based inhibition.
Which CYP isoforms can be evaluated in your inhibition assays?
We offer assays for the major drug-metabolizing CYP isoforms, including CYP1A2, 2C9, 2C19, 2D6, and 3A4, among others. The specific panel can be customized based on your compound's metabolic profile and the requirements of your development program.
What is the difference between fluorescent and LC-MS/MS-based assays?
Fluorescent assays use fluorogenic substrates and offer higher throughput, making them suitable for early screening. LC-MS/MS-based assays provide quantitative measurement of specific metabolite formation and are preferred for definitive IC50 determination and regulatory submissions. The choice depends on your stage of development and data requirements.
How is the IC50 value calculated from the assay data?
The IC50 value is calculated by measuring the decrease in metabolite formation in the presence of increasing concentrations of the test compound compared to a vehicle control. Nonlinear regression analysis is used to fit the inhibition curve and determine the concentration that produces 50% inhibition.
Can you assess CYP inhibition for veterinary drug candidates specifically?
Yes. While our assays use human enzyme sources for regulatory alignment, the principles of CYP-mediated drug interactions apply across species. We can discuss species-specific considerations and help you design studies that address the unique questions of veterinary drug development.
References
- Liu L, Mo M, Chen X. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer. J Exp Clin Cancer Res 2023 Apr 13. View on PubMed
- Yan Z, Caldwell GW. The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions. Curr Top Med Chem 2012. View on PubMed
- Halladay JS, Delarosa EM, Tran D. High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis. Drug Metab Lett 2011 Aug. View on PubMed
- Parrish KE, Mao J, Chen J. In vitro and in vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats. Biopharm Drug Dispos 2016 May. View on PubMed
- Riley RJ, Wilson CE. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling. Expert Opin Drug Metab Toxicol 2015 Apr. View on PubMed
- In vitro P450 inhibition assays are widely used to study potential drug-drug and drug-botanical interactions. High-Throughput Cytochrome P450 Cocktail Inhibition Assay for ... - PMC. Although these assays typically evaluate ... View article
De-risk Your Veterinary Drug Development
Contact our team to discuss your CYP inhibition assay needs. We'll help you design a study that delivers the data you need to make confident decisions about your candidates and combination therapy strategies.